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SchizophreniaAstrocytes express dopamine receptors and respond to dopamine stimulation. However, the role of astrocytes in
psychiatric disorders and the effects of antipsychotics on astroglial cells have only been investigated recently.
S100B is a glial-derived protein, commonly used as a marker of astroglial activation in psychiatric disorders,
particularly schizophrenia. We investigated S100B secretion in three different rat brain preparations (fresh
hippocampal slices, C6 glioma cells and primary astrocyte cultures) exposed to apomorphine and antipsychotics
(haloperidol and risperidone), aiming to evaluate, ex vivo and in vitro, whether dopamine activation and
dopaminergic antagonists modulate astroglial activation, as measured by changes in the extracellular levels of
S100B. The serum S100B elevation observed in schizophrenic patients is not reﬂected by the in vitro decrease of
S100B secretion that we observed in hippocampal slices, cortical astrocytes and C6 glioma cells treated with
apomorphine,whichmimicsdopaminergic hyperactivation. This decrease inS100B secretion canbeexplainedby
a stimulation of D2 receptors negatively coupled to adenyl cyclase. Antipsychotic medications and antioxidant
supplementation were able to prevent the decline in S100B secretion. Findings reinforce the beneﬁts of
antioxidant therapy inpsychiatricdisorders. Basedonour results, inhippocampal slices exposed to apomorphine,
it may be suggested that antipsychotics could help to normalize S100B secretion by astrocytes.and 2 dopamine receptor,
ay; GSH, reduced glutathione
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Schizophrenia is a chronic psychiatric disorder that affects
approximately 1% of the population, and its positive symptoms (e.g.,
hallucinations and delusions) are correlated with elevated dopami-
nergic activity (Guillin et al., 2007). The disruption of prepulse
inhibition of the acoustic startle response by the dopamine agonist
apomorphine in rats has been used in the last two decades as a model
of schizophrenia-related disorders, and this disruption is reversed by
both typical and atypical antipsychotic agents [e.g., (Mitchell and
Neumaier, 2008; Swerdlow et al., 1994)].
It is well known that astrocytes express dopamine receptors and
respond to dopamine stimulation (Hertz et al., 1984). However, the
role of astrocytes in psychiatric disorders (De Keyser et al., 2008) andthe effects of antipsychotics on astroglial cells have only been
investigated recently (Quincozes-Santos et al., 2008; Roh et al., 2008).
S100B is a calcium-binding protein synthesized and secreted by
astrocytes, and it is frequently used as a marker of astroglial activation
(Donato et al., 2009; Goncalves et al., 2008). However, its expression is
not restricted to astrocytes in the brain (Steiner et al., 2007) or even to
brain tissue (Goncalves et al., 2010).Many groups (including ours) have
reported S100B serum elevation in schizophrenic and bipolar patients
(Andreazza et al., 2007; Lara et al., 2001). In schizophrenia, some studies
have demonstrated increased S100B concentrations in the serum and
cerebrospinal ﬂuid (CSF), especially during acute stages of the disease
(Rothermundt et al., 2001; Schroeter et al., 2003). In addition, high
S100B concentrations were associated with negative or deﬁcit symp-
toms (Sarandol et al., 2007) with few exceptions (Schmitt et al., 2005).
More recently, a meta-analysis showed that serum S100B elevation is
related to the exacerbation phase in schizophrenic patients (Schroeter
et al., 2009).
Serum levels of S100B are elevated in untreated patients with
schizophrenia, in comparison with healthy controls (Lara et al., 2001;
Ling et al., 2007; Rothermundt et al., 2007), but the effect of antipsychotic
medication on S100B levels is still controversial. Increased (Ling et al.,
2007; Qi et al., 2009; Schroeter and Steiner, 2009;Wiesmann et al., 1999)
and decreased (Gattaz et al., 2000) levels of S100B were reported in
1292 P. Nardin et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 1291–1296medicated schizophrenic patients in comparison with healthy controls.
Some invitro studieshavecontributed to thisquestion (Quincozes-Santos
et al., 2008; Roh et al., 2008). As such, it has been suggested that elevated
levels of S100B in bodily ﬂuids from schizophrenic patients are
normalized rather than increased by antipsychotic drugs such as
haloperidol or clozapine (Steiner et al., 2010b). Despite these evidences,
it is not clear whether serum S100B only reﬂects astroglial activation
(Goncalves et al., 2010), particularly in schizophrenic patients (Steiner
et al., 2010c).
Some S100B secretagogues in astroglial cells have been identiﬁed,
including ﬂuoxetin (Tramontina et al., 2008), kainate (Sakatani et al.,
2008) and carbenoxolone, an inhibitor of gap junctions (Leite et al.,
2009). In addition, two reports suggest a regulatory effect of
antipsychotics on S100B secretion in C6 glioma cells and oligodendro-
cytic OLN-93 cells (Quincozes-Santos et al., 2008; Steiner et al., 2010b),
possibly mediated by dopamine receptors. Here we investigated S100B
secretion in three different rat brain preparations (fresh hippocampal
slices, C6 glioma cells and primary astrocyte cultures) exposed to
apomorphine and antipsychotics (haloperidol and risperidone), aiming
to evaluate ex vivo and in vitro whether dopamine activation and
dopaminergic antagonists modulate astroglial activation measured as
changes in the extracellular levels of S100B. S100B secretion is also
affected by antioxidant compounds (Donato et al., 2009), and
apomorphine has protective effects on oxidative stress-induced cell
death (Hara et al., 2006). Therefore, we also investigated the effect of
apomorphine together with other antioxidants on S100B secretion.
2. Methods
2.1. Animals
ThirtyWistar rats (twenty fourmale30-dayold rats for hippocampal
slices and six 1 or 2-day old rats for cell culture) were obtained from
our breeding colony (Department of Biochemistry, UFRGS, Porto
Alegre, Brazil), were maintained under controlled light and environ-
mental conditions (12 h light/12 h dark cycle at a constant temperature
of 22±1 °C), and had free access to commercial chow and water. All
animal experiments were carried out in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 80-23) revised in 1996 and followed the
regulations of the local animal housing authorities.
2.2. Chemicals
Poly-L-lysine, Dulbecco's modiﬁed Eagle's medium (DMEM), ﬂasks
andothermaterial for cell culture,monoclonal anti-S100B antibody (SH-
B1), 4-(2-hydroxyethyl)piperazene-1-ethanesulfonic acid (HEPES), O-
phenylenediamine (OPD), [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] (MTT), apomorphine, N-acetylcysteine (NAC),
and ascorbic acid (AA)were purchased from Sigma (St. Louis, MO, USA).
Glutathione monoethylester (GSH) was obtained from Calbiochem
(Darmstadt, Germany). Polyclonal Rabbit Anti-S100 was obtained from
Dako (Glostrup, Denmark). Anti-rabbit IgG Horseradish Peroxidase was
obtained from Amersham (Buckingamshire, UK). Fetal calf serum (FCS)
was purchased from Gibco (Belo Horizonte, Brazil). Risperidone
(Risperdal®) and haloperidol (Haldol®) were a gift from Janssen-Cilag
(São Paulo, Brazil), a Brazilian division of Johnson & Johnson.
2.3. Hippocampal slice preparation
This procedurewas carried out asdescribedpreviously (Nardin et al.,
2009). Brieﬂy, rats were decapitated, and their hippocampi quickly
dissected out. Transverse sections (300 μm) were rapidly obtained
with aMcIlwain tissue chopper. One slicewas placed into eachwell of a
24-well culture plate. Slices were incubated at room temperature in a
HEPES-buffered saline solution (HBSS) containing (in mM): 120 NaCl;2 KCl; 1 CaCl2; 1 MgSO4; 1 KH2PO4; 10 glucose and 25 HEPES, pH 7.4.
The medium was changed every 15 min with fresh medium. After a
120-min equilibration period, the slices were incubated for 1 h for
S100B secretion assay at 30 °C in the HBSS medium in the absence or
presenceof apomorphine(1, 10or100 μM);haloperidol, risperidone,N-
acetylcysteine (NAC), glutathione monoethylester (GSH), and ascorbic
acid were added to the incubation medium at the concentrations
indicated in the Results section. Ten microliters of medium were
collected for S100B measurement.
2.4. Astrocyte culture
Primary cortical astrocyte cultures fromWistar rats were prepared
as previously described (Gottfried et al., 2003). All procedures were in
accordance with the NIH guidelines for the care and use of laboratory
animals and were approved by the ethical committee from the
University (UFRGS, Porto Alegre, Brazil). Brieﬂy, cortices of newborn
Wistar rats (1–2 days old) were removed and mechanically dissoci-
ated in Ca2+ and Mg2+-free balanced salt solution. The cortex was
cleaned of meninges and mechanically dissociated by sequential
passage through a Pasteur pipette. After centrifugation at 1000 rpm
for 5 min, the pellet was resuspended in DMEM (pH 7.6) supple-
mented with 8.39 mM HEPES, 23.8 mM NaHCO3, 0.1% Fungizone®,
0.032% garamicine and 10% FCS. Cultures were maintained in DMEM
containing 10% FCS in 5% CO2/95% air at 37 °C and allowed to grow to
conﬂuence. Themediumwas replaced by DMEMwithout serum in the
absence or presence of apomorphine, haloperidol or risperidone (at
concentrations indicated in the Results section). After 1 or 24 h of
incubation, aliquots of 50 µL of media were collected for S100B
measurement.
2.5. C6 glioma cells
A rat glioblastoma cell line was obtained from the American Type
Culture Collection (Rockville, Maryland, USA). Late passage cells (i.e.,
after at least 100 passages)were seeded in 24-well plates at densities of
104 cells/well and cultured in DMEM (pH 7.4) supplemented with 5%
FCS, 2.5 mg/mL amphotericin B and 100 U/L gentamicin in 5% CO2/95%
air at 37 °C (de Souza et al., 2009). When the cells reached conﬂuence,
the culture medium was replaced by DMEM without serum in the
absence or presence of apomorphine, haloperidol or risperidone (at
concentrations indicated in the Results section). After 1 or 24 h of
incubation, aliquots of 50 µL of media were collected for S100B
measurement.
2.6. ELISA for S100B
The S100B concentration was measured as described previously
(Leite et al., 2008). Brieﬂy, 50 μL of sample plus 50 μL of Tris buffer
were incubated for 2 h in a microtiter plate previously coated with
monoclonal anti-S100B. Polyclonal anti-S100 was incubated for
30 min, and then peroxidase-conjugated anti-rabbit antibody was
added for a further 30 min. The color reaction with o-phenylenedia-
mine was measured at 492 nm. The standard S100B curve ranged
from 0.002 to 1 ng/mL.
2.7. MTT reduction assay
Viabilitywasassayedvia the colorimetricMTTmethod (Hansen et al.,
1989). Brieﬂy, the cells or slices were incubated with 0.5 mg/mL MTT
followed by incubation in 5%CO2/95% air at 37 °C or at 30 °C for 30 min,
respectively. The formazanproduct generatedduring the incubationwas
solubilized in dimethyl sulfoxide (DMSO). Absorbance values were
measured at 560 and 630 nm. The results are expressed as a percentage
of the control.
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LDH activity in the incubation medium was determined by a
colorimetric commercial kit (from Doles, Brazil) according to the
manufacturer's instructions.2.9. Statistical analysis
Data are reported as the mean±SEM and were analyzed by one-
way analysis of variance (ANOVA) followed by Duncan's test or by
Student's t test when indicated in the Results section and performed
in SPSS-16.0. Values of pb0.05 were considered signiﬁcant.Fig. 2. Apomorphine decreases S100B secretion in astrocytes and C6 glioma cells. S100B
secretion at 1 h (in panel A) and 24 h (inpanel B) inprimary astrocyte cultures (openbars)3. Results
A curve of the effect of apomorphine from 1 to 100 μM on S100B
release is shown in Fig. 1A.We found a signiﬁcant effect of apomorphine
(one-wayANOVA, F3, 39=8.254; pb0.001). A post-hocDuncanmultiple
range test showed that, at 100 μM, apomorphine was able to decrease
S100B release in acute hippocampal slices (pb0.05, compared to all the
other groups). A decreasing trend was observed with apomorphine at
10 μM (pN0.05). Two assays were performed in parallel to evaluate cell
integrity and viability: LDH release (data not shown) andMTT reduction
(Fig. 1B), respectively; these results allowS100B release tobe referred to
more appropriately as S100B secretion.
At 100 μM apomorphine was also able to reduce S100B secretion by
primary astrocytes and C6 glioma cells (Fig. 2). In astrocyte cultures, this
effect was observed at 1 h (Student's t test, p=0.024) and 24 h after
apomorphine addition (p=0.045) (Fig. 2A and B, respectively).Fig. 1. S100B secretion is negatively modulated by apomorphine in acute hippocampal slices.
In A, S100Bwas released fromhippocampal slices incubatedwith apomorphine (at indicated
concentrations) for 60 min. S100B was measured by ELISA. Each value is the mean
(± standard error) of six independent experiments performed in triplicate. * signiﬁcantly
different from respective basal S100B secretion, taken as 100% (one-way ANOVA followed
by Duncan's test; pb0.05). In B, an MTT reduction assay in hippocampal slices incubated
with apomorphine (at the indicated concentrations) for 60 min. Each value is the mean
(± standard error) of six independent experiments performed in triplicate.
and in C6 glioma cells (gray bars) incubated in serum-free medium containing 100 μM
apomorphine. S100Bwasmeasured byELISA. Each value is themean (±standard error) of
six independent experiments performed in triplicate. * signiﬁcantly different from
respective basal S100B secretion (without apomorphine) (Student's t test; pb0.05). ND
(notdetected)means thatneitherbasal nor apomorphine-modulated S100B secretionwas
detected at 1 h in C6 cell preparations.Unfortunately, in our C6 cell preparations, we only found measurable
extracellular levels of S100B at 24 h (p=0.015) (Fig. 2B).
The effects of antipsychotics on S100B secretion were evaluated in
acute hippocampal slices (Fig. 3A). At 10 μM, neither haloperidol
nor risperidone were able to alter basal S100B secretion per se
(F2, 30=0.915; p=0.411). However, in the presence of apomorphine,
risperidone (F2, 17=5.758;p=0.012), butnothaloperidol (F2, 17=1.971;
p=0.170) increased S100B secretion when compared to haloperidol
alone, but the level was not different from basal S100B secretion. The
effects of the antipsychoticswere also investigated inastrocyte andC6cell
cultures (Fig. 3B). In primary astrocytes, no effect of either haloperidol or
risperidone was observed on S100B secretion at 24 h. However,
haloperidol (but not risperidone) decreased S100B secretion at 1 h
(one-wayANOVA, pb0.05; datanot shown). Conversely, risperidone (but
not haloperidol) was able to induce an increase of S100B secretion (one-
way ANOVA, F2, 24=16.703; pb0.001) in C6 cell cultures.
To investigatewhether the S100Bdecrease inducedby apomorphine
was related to its ability to counteract oxidative stress, we investigated
this effect in acute hippocampal slices treated with other antioxidant
compounds: glutathione (GSH), N-acetyl-cysteine (NAC) and ascorbic
acid (AA) (Fig. 4A). Interestingly, GSH (but not NAC or AA) induced an
increase in S100B secretion (one-wayANOVA, F3,19=12.792; pb0.001).
However, all antioxidant compounds (in the presence of 100 μM
apomorphine) were able to restore basal levels of S100B secretion.
Moreover, because some antipsychotics appear to block certain
oxidative stress signals, we performed co-incubations of the antipsy-
chotics with glutathione (Fig. 4B). Haloperidol switched off GSH-
induced S100B secretion (Student's t test, p=0.850), but risperidone
was able to maintain this effect (p=0.017).
Fig. 3. Antipsychotics prevent the apomorphine-induced decrease of S100B secretion. In A,
S100B secretion at 1 h in acute hippocampal slices in the presence or absence of
apomorphine (at 100 μM) and exposed to antipsychotics (haloperidol or risperidone at
10 μM). S100B was measured by ELISA. Each value is the mean (± standard error) of six
independent experiments performed in triplicate. * signiﬁcant difference between
risperidone groups in the presence and absence of apomorphine (one-way ANOVA
followed by Duncan's test; pb0.05). However, none of the antipsychotics differed from
basal secretion. In B, primary astrocyte cultures (open bars) or C6 glioma cells (gray
bars) incubated in serum-free medium containing haloperidol or risperidone at 10 μM.
Each value is the mean (± standard error) of six independent experiments performed
in triplicate. Extracellular S100B at 24 h was measured by ELISA * signiﬁcantly different
from respective basal S100B secretion (one-way ANOVA followed by Duncan's test;
pb0.05).
Fig. 4. Antioxidants also prevent the apomorphine-induced decrease of S100B secretion.
In A, S100B secretion at 1 h in acute hippocampal slices in the presence or absence of
apomorphine (at 100 μM) and exposed to antioxidants (NAC, N-acetyl-cysteine; GSH,
glutathione monoethylester; or AA, ascorbic acid, all at 100 μM). Extracellular S100B
was measured by ELISA. Each value is the mean (± standard error) of six independent
experiments performed in triplicate. * signiﬁcantly different from basal S100B secretion
(one-way ANOVA followed by Duncan's test; pb0.05). In B, S100B secretion at 1 h in
acute hippocampal slices in the presence of GSH (at 100 μM) and haloperidol or
risperidone (at 10 μM). Extracellular S100B was measured by ELISA. Each value is the
mean (± standard error) of six independent experiments performed in triplicate.
* signiﬁcantly different from basal S100B secretion (Student's t test; pb0.05).
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Apomorphine is able to activate both D1- and D2-like receptors.
These receptors apparently have opposing effects on signaling mole-
cules such as cAMP (i.e., D1 activation increases cAMP while D2
decreases cAMP). An electrophysiological study on cortical slices
suggested that D1 and D2 are activated at dopamine concentrations
higher than 0.5 μM, and that D2 activation overrides D1 activation
(Trantham-Davidson et al., 2004). Moreover, D2 receptors are strongly
expressed in astrocytes (Khan et al., 2001). Therefore, astrocytes could
be important targets of D2 antagonists and typical antipsychotics, and
they may be involved in the pathogenesis of schizophrenia.
Here we found that apomorphine at 100 μM was able to reduce
S100B secretion in hippocampal slices, primary cortical astrocytes and
C6 glioma cells. Assuming that D2 receptors in astrocytes of these
preparations are negatively coupled to adenyl cyclase, a decrease in
S100B secretion would be an expected result. Other results with
forskolin, ﬂuoxetin and serotonin suggest a connection between cAMP
and S100B secretion (Goncalves et al., 2002; Tramontina et al., 2008).
In schizophrenic patients, dopaminergic hyperactivation has been
proposed to underlie the exacerbation of positive symptoms, which is
where typical antipsychotics are most effective. Therefore, ignoring
the effects of other S100B secretagogues on astrocytes, a decrease ofS100B secretion would be expected from these cells in schizophrenic
patients. Conversely, increased serum S100B has been observed in
schizophrenic patients in multiple studies (Lara et al., 2001;
Rothermundt et al., 2004; Schroeter et al., 2009). However, it remains
unclear whether elevated serum S100B speciﬁcally reﬂects astroglial
activation. In fact, extra-cerebral sources can contribute to serum
S100B, particularly adipocytes (Goncalves et al., 2010). Moreover,
recent ﬁndings strongly suggest that S100B levels in the blood
correlate with adipose tissue in normal individuals (Steiner et al.,
2010a) and with insulin resistance in schizophrenic patients (Steiner
et al., 2010c) . Our data therefore suggest that the serum S100B
elevation observed in schizophrenic patients is not necessarily due to
astroglial activation by dopaminergic hyperactivation. Other cell
sources of S100B and/or other S100B secretagogues must be involved
in that elevation.
Moreover, the effect of antipsychotics on peripheral S100B in
schizophrenic patients is also a matter of controversy. In fact, clinical
studies have shown both increases (Qi et al., 2009; Schmitt et al., 2005;
Schroeter et al., 2003; Wiesmann et al., 1999) and decreases (Gattaz
et al., 2000; Ling et al., 2007; Steiner et al., 2009) of blood S100B that
could be related to antipsychotic medication. Two previous studies
addressed this question by investigating the in vitro effect of
antipsychotics on S100B secretion in glial cells. C6 glioma cells treated
with risperidone (10–40 μM) exhibited an increase of S100B secretion
(Quincozes-Santos et al., 2008), whereas C6 glioma cells and oligoden-
drocytic OLN-93 cells treated with haloperidol (1 μg/mL or 2.7 μM) or
clozapine (10 μg/mL or 30 μM) exhibited a decrease in S100B secretion
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could be due to differences in multiple conditions (drugs, concentra-
tions, serum-containing medium, cell types and metabolic conditions).
Under our conditions, neither haloperidol nor risperidone (both at
10 μM) affected basal S100B secretion in two investigated preparations,
hippocampal slices (1 h) and cortical astrocyte cultures (24 h), but we
observed an increase in S100B secretion (24 h) inC6 glioma cells treated
with riperidone. Interestingly, a transitory decrease of S100B secretion
(1 h) was observed in astrocyte cultures exposed to haloperidol.
Although C6 cells and astrocytes have been assumed indistinctly to be
astroglial cells, many discrepancies between them have been observed
[e.g., (Nardin et al., 2007)], and these could partially explain our results.
For instance, concerning dopaminergic communication, dopamine
stimulation is able to up-regulate glutathione in astrocytes but not in
C6 glioma cells (Han et al., 1996).
It is quite difﬁcult to project our in vitro S100B secretion results with
astrocyte preparations and brain slices onto the changes in peripheral
S100B that occur in schizophrenic patients under long-termmedication.
However, based on our results in hippocampal slices exposed to
apomorphine, it is possible to speculate that antipsychotics help to
normalize S100B secretion by astrocytes, as previously suggested by
Steiner's group (Steiner et al., 2010b). However, it is not clear whether
this is mediated by dopamine or another neurotransmitter receptor.
Due to the protective effect of antipsychotic medications against
oxidative stress, we decided to investigate the effect of classical
antioxidants (NAC, glutathioneandascorbic acid) on theS100Bsecretion
decrease induced by apomorphine in hippocampal slices. All of the
antioxidants were able to normalize S100B secretion, but glutathione
was also able to induce an increase of S100B secretion. This aspect is very
interesting because glutathione is not only a free radical scavenger but is
also exported by astrocytes. This compound has extracellular activity on
some ion channels and G protein-coupled receptors (Wang et al., 2006),
and this could directly or indirectly modulate S100B secretion, the
mechanism of which remains unknown (Donato et al., 2009). Note that
haloperidol, but not risperidone, somehow affected this glutathione-
induced S100B secretion. This reinforces the idea that typical antipsy-
chotics such as haloperidol might aggravate the oxidative stress
observed in schizophrenic patients (Ng et al., 2008; Pillai et al., 2007).
Nevertheless, our data support the idea that antioxidant therapy is useful
for preventing some neurochemical alterations in schizophrenia,
particularly astroglial S100B secretion, even taking into account all of
the limitations of this in vitro study associated with using apomorphine
to induce dopaminergic hyperactivation.
It is important to mention some limitations of this study. First, we
examined S100B secretion in hippocampal slices, but other brain regions,
e.g. prefrontal cortex, deserve further investigation due to their
importance in schizophrenia [e.g. (Artigas, 2010)]. Secondly, we focused
our discussion about schizophrenia based on alterations in dopaminergic
neurotransmission. However, other hypotheses must be considered,
particularly those based on altered glutamatergic communication. In fact,
an intricate linkage between glutamatergic and dopaminergic systems
offers a wide comprehension about schizophrenia alterations, including
oxidative stress. The glutamatergic hypothesis for schizophrenia, for
example, suggests that NMDA receptor hypofunction leads to an
increased glutamatergic transmission in the prefrontal cortex (Gunduz-
Bruce, 2009). In support of this, we found that elevated levels of
glutamate, like apomorphine, decreased S100B secretion (Nardin et al.,
2009; Tramontina et al., 2006). However, as discussed before, this
decrease in secretion contrasts with the serum S100B elevation observed
in schizophrenic patients, possibly because extracerebral sources con-
tribute to serum S100B (Goncalves et al., 2010; Steiner et al., 2010a,
2010c). Thirdly, the effect of risperidone is not limited to receptors of
dopamine, and serotonin receptors are possibly involved in the observed
effects. This aspect helps to explain some differences observed with
haloperidol and risperidone, in agreement with previous studies
(Quincozes-Santos et al., 2008).5. Conclusions
Our data on astroglial S100B secretion were analyzed in light of the
potential use of S100B as a marker of astroglial activation in psychiatric
disorders, particularly schizophrenia. However, the serum S100B
elevation observed in schizophrenic patients does not ﬁt with the in
vitro decrease of S100B secretion we observed in hippocampal slices,
cortical astrocytes and C6gliomacells treatedwith apomorphine,which
mimics dopaminergic hyperactivation. This decrease of S100B secretion
can be explained by the stimulation of D2 receptors negatively coupled
to adenyl cyclase. Antipsychotic medication and antioxidant supple-
mentation were able to prevent the decline in S100B secretion. This
reinforces the beneﬁts of antioxidant therapy in psychiatric disorders.
Moreover, our data suggest thatmore caution should be exercisedwhen
interpreting changes in peripheral S100B levels as a sign of astroglial
activation, particularly considering the extra-cerebral sources of this
protein.
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